These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
65. Management of glucocorticoids-induced osteoporosis: role of teriparatide. Migliaccio S; Brama M; Malavolta N Ther Clin Risk Manag; 2009 Apr; 5(2):305-10. PubMed ID: 19536312 [TBL] [Abstract][Full Text] [Related]
66. Prevention and treatment of systemic glucocorticoid side effects. Moghadam-Kia S; Werth VP Int J Dermatol; 2010 Mar; 49(3):239-48. PubMed ID: 20465658 [TBL] [Abstract][Full Text] [Related]
67. [How can corticosteroid-induced osteoporosis be prevented and treated?]. Orozco P; Zwart M Med Clin (Barc); 2003 Nov; 121(16):639. PubMed ID: 14636548 [No Abstract] [Full Text] [Related]
68. [How can we treat or prevent corticosteroid-induced osteoporosis?]. Danés I; Bosch M Med Clin (Barc); 2003 Apr; 120(12):473-5. PubMed ID: 12689556 [No Abstract] [Full Text] [Related]
69. Management of corticosteroid-induced osteoporosis. UK Consensus Group Meeting on Osteoporosis. Eastell R J Intern Med; 1995 May; 237(5):439-47. PubMed ID: 7738483 [TBL] [Abstract][Full Text] [Related]
70. Animal models to explore the effects of glucocorticoids on skeletal growth and structure. Wood CL; Soucek O; Wong SC; Zaman F; Farquharson C; Savendahl L; Ahmed SF J Endocrinol; 2018 Jan; 236(1):R69-R91. PubMed ID: 29051192 [TBL] [Abstract][Full Text] [Related]
71. How to manage patients on long-term oral corticosteroids: recommendations from available guidelines. Pal B Clin Exp Rheumatol; 1997; 15(4):341-2. PubMed ID: 9272291 [No Abstract] [Full Text] [Related]
72. 'Down to skin and bone'. Cameron F Australas J Dermatol; 2000 Aug; 41(3):146-8. PubMed ID: 10954984 [No Abstract] [Full Text] [Related]
73. Understanding and Managing Corticosteroid-Induced Osteoporosis. Kobza AO; Herman D; Papaioannou A; Lau AN; Adachi JD Open Access Rheumatol; 2021; 13():177-190. PubMed ID: 34239333 [TBL] [Abstract][Full Text] [Related]
74. Review: corticosteroid usage: observations at a community hospital. Pensabeni-Jasper T; Panush RS Am J Med Sci; 1996 May; 311(5):234-9. PubMed ID: 8615399 [TBL] [Abstract][Full Text] [Related]
75. Managing corticosteroid induced osteoporosis in medical outpatients. Bell R; Carr A; Thompson P J R Coll Physicians Lond; 1997; 31(2):158-61. PubMed ID: 9131514 [TBL] [Abstract][Full Text] [Related]
76. New aspects of the mechanism of corticosteroid-induced dermal atrophy. Oikarinen A; Autio P Clin Exp Dermatol; 1991 Nov; 16(6):416-9. PubMed ID: 1806315 [TBL] [Abstract][Full Text] [Related]
77. Implementation of recommendations for prevention of glucocorticosteroid-induced osteoporosis in hospitalized patients. Gazitt T; Elias M; Feld J; Lavi I; Haddad A; Bishara-Garzuzi R; Elhija MA; Kibari A; Zisman D Clin Rheumatol; 2021 Oct; 40(10):4361-4363. PubMed ID: 34159492 [No Abstract] [Full Text] [Related]
78. [Which adjuvant measures should be associated with long-term oral corticosteroid therapy in inflammatory diseases? A summary of existing French recommendations]. Hoefsloot S; Urbanski G; Lacout C; Bouvard B; Lavigne C Rev Med Interne; 2021 Sep; 42(9):616-624. PubMed ID: 34148673 [TBL] [Abstract][Full Text] [Related]
79. [Prevention and treatment of corticosteroid induced osteoporosis. Clinical Guidelines.]. Guðmundsson A; Helgason S; Gudbjornsson B Laeknabladid; 2002 Feb; 88(2):101-7. PubMed ID: 16940654 [TBL] [Abstract][Full Text] [Related]
80. Side effects of chronic systemic glucocorticoid therapy: what dermatologists should know. Tavares LCP; Caetano LVN; Ianhez M An Bras Dermatol; 2024; 99(2):259-268. PubMed ID: 38007314 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]